Hot Pre-Market Trades in US Stocks
VS MEDIA, down 9.46% in pre-market, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Entegris is up 8.54% in pre-market. Based on recent key news:
<ol>
<li>
On February 10, Entegris won the patent lawsuit against Zhaojie, eliminating legal risks. This ruling confirms Zhaojie's independent research and intellectual property protection of core technologies and advanced process products, boosting market confidence and driving up Entegris's stock price.
</li>
<li>
On February 9, Entegris's peers in the semiconductor manufacturing sector performed strongly, uplifting market sentiment. Teradyne and Kulicke and Soffa's performances exceeded expectations, pushing Entegris's stock price up 20.6% over the past month.
</li>
<li>
On February 9, Entegris's management provided earnings guidance for the fourth quarter of 2025, expecting earnings per share between $0.62 and $0.69, with optimistic market expectations. The semiconductor industry has performed strongly recently, with significant capital inflow.
</li>
</ol>
Top Gainers in Pre-Market US Stocks
Abpro is up 86.84% in pre-market. Based on recent key news:
<ol>
<li>On February 10, Abpro Holdings's stock price rose as Goldman Sachs Group disclosed in a 13G filing that it holds 6.8% of the company's shares. This news boosted market confidence in Abpro, driving the stock price significantly higher. There is increased interest in biotech stocks.</li>
</ol>
Quince Therapeutics is up 65.15% in pre-market. Based on recent news:
<ol>
<li>
On February 9, Quince Therapeutics announced the hiring of LifeSci Capital as a financial advisor to help explore restructuring and evaluate strategic options. The company stated it may consider partnerships, joint ventures, mergers and acquisitions, licensing, or other strategic transactions. This news boosted market confidence and drove the stock price up.
</li>
<li>
On February 10, Quince Therapeutics's stock price rose 54.15% in pre-market trading, reaching $0.20. According to Benzinga Pro data, this increase reflects the market's positive response to the company's restructuring plans.
</li>
<li>
Over the past 12 months, Quince Therapeutics's stock price has fallen 90.91%, nearing a 52-week low. Although the RSI indicates the stock is oversold, the MACD remains below the signal line, suggesting an overall bearish trend. Nevertheless, analysts still give the stock a buy rating. The biotechnology sector has shown volatility recently, and investors should be cautious.
</li>
</ol>
Haverty Furniture-A is up 39.32% in pre-market, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation

VSME

ENTG

VS MEDIA pre-market down 9.46%; Entegris pre-market up 8.54%; Abpro pre-market up 86.84%; Quince Therapeutics pre-market up 65.15%; Haverty Furniture-A pre-market up 39.32%

Pre-market hot trades in US stocks: VS MEDIA pre-market down 9.46%; Entegris pre-market up 8.54%